AbbVie (ABBV) vs Amgen (AMGN): Growth Narratives After Major Patent Losses
Key Takeaways
- ABBV is successfully replacing declining Humira sales with rapid growth from Skyrizi and Rinvoq, driving double-digit revenue expansion in recent quarters.
- AMGN is growing through patent expirations on Prolia and Xgeva, powered by six key growth drivers that now represent roughly 70% of product sales.
- Both companies are large-cap biopharmaceutical leaders, but ABBV carries a materially larger market capitalization and higher dividend yield than AMGN.
- Relative performance favors ABBV over the recent stretch, with a stronger year-to-date advance than AMGN.
- AMGN carries distinct catalysts, including its MariTide obesity candidate and oncology pipeline, alongside an unresolved tax dispute with the IRS (Internal Revenue Service).
Why This Comparison Matters
AbbVie and Amgen stand among the largest pharmaceutical companies investors track closely, yet each follows a distinct path forward. This comparison helps traders and long-term holders assess how the two are handling the loss of exclusivity on major products, their relative market positions, and what that means for performance and dividends. Both generate strong cash flows, but their pipelines, upcoming catalysts, and risk factors differ enough to warrant a closer look at which profile aligns better with individual goals in today’s environment.
AbbVie’s Transition Story
ABBV operates as a research-focused biopharmaceutical firm based in North Chicago, Illinois, with key areas in immunology, oncology, neuroscience, and aesthetics. Its position has improved lately as newer treatments offset the impact from Humira’s U.S. exclusivity loss in 2023. Skyrizi and Rinvoq now serve as the main immunology growth engines, while neuroscience products including Vraylar, Ubrelvy, Qulipta, and Vyalev provide an additional growth layer. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market action has been positive, with the stock up roughly 20% or more year-to-date at recent peaks. The company raised its full-year revenue outlook and completed the acquisition of Apogee Therapeutics to strengthen its next-generation immunology efforts. Two FDA Breakthrough Therapy designations for an investigational cancer drug added further support. The stock trades near the sector average on a forward P/E basis, with a dividend yield around 2.5%.
Amgen’s Springboard Approach
AMGN is headquartered in Thousand Oaks, California, and maintains a broad portfolio across cardiovascular, bone health, inflammation, oncology, rare disease, and biosimilars. Its recent results reflect a strategy of using fast-growing products to counter competition facing the denosumab franchise of Prolia and Xgeva.
Recent quarters showed solid breadth. Six key growth drivers, such as Repatha, Evenity, and Tezspire, accounted for about 70% of product sales and rose roughly 24% year over year as a group. Amgen exceeded quarterly estimates and lifted its full-year revenue and earnings guidance, aided by strong Repatha and Uplizna performance. The company ended one obesity candidate but continues advancing MariTide toward key data readouts. An ongoing IRS dispute over earlier tax years remains a consideration, along with an FDA proposal on Tavneos.
Direct Comparison
Both firms face the core issue of managing exclusivity losses on former blockbusters. AbbVie has made more headway, with Skyrizi and Rinvoq already compensating for Humira’s decline, while Amgen continues to address faster erosion in Prolia and Xgeva. Growth sources also differ: AbbVie relies primarily on two immunology assets plus an expanding neuroscience portfolio, whereas Amgen spreads its momentum across six product groups that include biosimilars and rare-disease treatments.
Market sentiment has leaned toward AbbVie lately, shown in stronger relative performance and lower beta. Amgen holds a potentially larger catalyst with MariTide in the obesity space, though pivotal data is not anticipated until 2027. Risk profiles vary as well: AbbVie must contend with patent timelines on Skyrizi and Rinvoq over the coming decade, while Amgen navigates biosimilar pressure, cost-of-sales headwinds, and the unresolved IRS matter.
Where the Data Points
Considering factors such as trend consistency, stability, and relative positioning, the assessment favors ABBV in the present setting. The stock has shown steadier upward movement, reduced volatility, and a more defined near-term revenue path through already-approved immunology and neuroscience products. AMGN keeps meaningful longer-term potential in MariTide and its oncology efforts, yet its nearer-term outlook hinges more on managing biosimilar effects and regulatory items. This view remains probabilistic and tied to current information rather than a firm prediction.
Leveraging Tickeron AI for Deeper Insights
When evaluating names like these, I frequently consult Tickeron’s Trending AI Robots to review automated strategies that align with current market conditions. The platform highlights bots with favorable signals across various styles and timeframes, offering a practical way to explore data-driven approaches in sectors such as biotech without starting from scratch.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
AMGN in downward trend: 10-day moving average broke below 50-day moving average on October 12, 2026
The 10-day moving average for AMGN crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 53%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AMGN as a result. In 34 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 45%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 47%.
The Aroon Indicator for AMGN entered a downward trend on September 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AMGN's RSI Oscillator exited the oversold zone, 20 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 33 of 56 cases where AMGN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 59%.
The Moving Average Convergence Divergence (MACD) for AMGN just turned positive on September 24, 2026. Looking at past instances where AMGN's MACD turned positive, the stock continued to rise in 34 of 48 cases over the following month. The odds of a continued upward trend are 71%.
AMGN moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMGN advanced for three days, in 191 of 313 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
AMGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.342) is normal, around the industry mean (19.199). P/E Ratio (25.971) is within average values for comparable stocks, (34.793). Projected Growth (PEG Ratio) (2.524) is also within normal values, averaging (5.738). Dividend Yield (0.024) settles around the average of (0.025) among similar stocks. P/S Ratio (5.371) is also within normal values, averaging (4.033).
The Tickeron Profit vs. Risk Rating rating for this company is 8 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 64, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 15 (best 1 - 100 worst), indicating outstanding price growth. AMGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of human therapeutic products based on cellular biology
Industry PharmaceuticalsMajor
Advertisement